CTOs on the Move


 
DRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.drx.com
  • 3530 Wilshire Blvd Ste 1500
    Los Angeles, CA USA 90010
  • Phone: 800.379.9060

Executives

Name Title Contact Details

Similar Companies

SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northwind Pharmaceuticals

Northwind provides a complete pharmaceutical dispensing solution for medical clinics coast to coast, from packaging to software. Learn more.

SubjectWell

SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize.

Archemix

Archemix Corp. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.